Member access

4-Traders Homepage  >  Shares  >  London Stock Exchange  >  AstraZeneca plc    AZN   GB0009895292


News SummaryMost relevantAll newsSector news 

UK Health Watchdog Backs Lung Cancer Drug From Roche

05/09/2012 | 07:16pm US/Eastern

The U.K.'s health-care watchdog said in final draft guidance Thursday that it is recommending the use of Roche Holding AG's (ROG.VX) Tarceva as a treatment option for advanced-stage lung-cancer patients.

The National Institute for Health and Clinical Excellence, known as NICE, decides what medicines should be used in the U.K.'s publicly-funded National Health Service. It said the drug--whose chemical name is erlotinib--is a cost-effective use of NHS resources.

NICE, which has already recommended AstraZeneca PLC's (>> AstraZeneca plc) Iressa, or gefitinib, for non-small-cell lung cancer, said that while there isn't any trial data directly comparing the two drugs, clinical specialists say the drugs are "very similar and equally as effective."

"We are pleased to be able to recommend another treatment option for this stage of the disease," said NICE Director Carole Longson.

The watchdog said its decision to back the drug came after it requested more information about it from the Swiss drug maker.

Roche wasn't immediately available for comment.

NICE said the draft guidance is now with consultees, who have the opportunity to appeal against it.

-By Marta Falconi, Dow Jones Newswires; +41 43 443 8043;

Stocks mentioned in the article : AstraZeneca plc, AstraZeneca plc
React to this article
Latest news on ASTRAZENECA PLC
03:06p Alexion to bolster rare disease offering with $8.4 billion deal
05/05DJArdelyx's Mid-Stage Clinical Trial Fails to Meet Primary EndPoint
05/05 Global cancer drug spending hits $100 billion in 2014 - IMS Health
05/05 NEKTAR THERAPEUTICS : Posts Financial Results for the First Quarter of 2015
05/05 DEPOMED : Atossa Genetics Hires Cindy Atha as Vice President of Sales and Market..
05/03DJMyriad Genetics Fights Off Threats From Rivals
05/03 ASTRAZENECA : Prescription data show cost trends
05/01 ASTRAZENECA : Non-Executive Directors Buy Shares (DIRECTOR DEALINGS)
04/30 EXCLUSIVE : Pfizer is mystery bidder for rare disease drugmaker Sobi - sources
04/30 ASTRAZENECA : Medimmune and Immunocore announce new collaboration to conduct imm..
Duration : Period :
AstraZeneca plc Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes